3d agoThe FlyBULLISH 64Analyst
Archived explainer. For the current picture see today's BEAM page.
Why Is BEAM THERAPEUTICS IN (BEAM) Stock Down Today?
By the Top Tier Newswire AI Desk · November 10, 2026 at 1:03 PM ET · reviewed against 4 wire stories
BEAM THERAPEUTICS IN (BEAM) is down -10.23% in the latest session. Our newswire has captured 4 stories on BEAM across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Beam Therapeutics shares fell 10.23% to close at $24.25. The decline occurred despite the company announcing positive topline pivotal data from its BEACON Phase 1/2 trial. The stock dropped after the announcement, a pattern often seen when positive news is already priced in or when the market focuses on the long timeline for commercialization.
What Happened
Beam Therapeutics reported that its cell therapy, risto-cel, met the primary efficacy endpoint in the BEACON trial. The endpoint was freedom from severe vaso-occlusive crises for at least 12 consecutive months, based on independently adjudicated results. The company stated that the therapy met all primary endpoints in this single-arm Phase 1/2 study.
Following the data release, Wall Street analysts adjusted their outlooks. Wedbush raised its price target to $33 from $30. Guggenheim maintained its Buy rating but lowered its price target to $51. JonesTrading initiated coverage on the stock with a Buy rating. Despite these supportive ratings, the stock price declined significantly during the session.
What The Data Shows
The stock had been trending downward prior to the announcement, moving down 6.3% over the last eight sessions from $28.84 to $27.02. On the day of the drop, the stock printed three fresh 52-week highs and 36 fresh 52-week lows, indicating high volatility and a wide trading range.
Insider activity in the last 90 days showed no buys and two sells totaling $1.2 million. CEO John M. Evans sold shares on October 15, 2026, and SVP and Treasurer Bethany J. Cavanagh sold on October 1, 2026. The broader sentiment trend has been deteriorating, with the 30-day average at 56 out of 100 and the last seven days at 52 out of 100.
What To Watch
Investors will monitor the company's plans to file a Biologics License Application as early as year-end 2026. The market will also watch how the stock stabilizes after the sharp decline, particularly given the recent insider selling and the mixed analyst reactions to the pivotal data.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
BEAM by the numbers
Last: $24.25Session: -10.23%7 sessions: -7.64%Coverage: 4 stories / 3 sourcesAI sentiment: 56/100 (mixed)
The headlines behind the move
3d agoGuruFocusBEARISH 42Product/PR
Beam Therapeutics (BEAM) Shares Fall Despite Positive Sickle Cell Trial Results
3d agoBusiness InsiderBEARISH 38General
Beam drops despite Phase 1/2 trial win for cell therapy in sickle cell disease
Beam Therapeutics (BEAM) stock falls despite a Phase 1/2 trial win for cell therapy risto-cel in sickle cell disease. Read more here.
3d agoBusiness InsiderBULLISH 78Product/PR
Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease
BEACON Trial Achieved Primary Efficacy Endpoint of Freedom from Severe Vaso-occlusive Crises (VOCs) for at Least 12 Consecutive Months, Based on Independently Adjudicated Results, and Met All Primary...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on BEAM: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier BEAM move explainers: 2026-11-10 · 2026-10-29 · 2026-10-28 · 2026-09-09 · 2026-09-08 · 2026-08-26 · 2026-08-25 · 2026-08-20